MLICM
ZVRA icon

Metropolitan Life Insurance Company (MetLife)’s Zevra Therapeutics ZVRA Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-993
Closed -$5.76K – 2163
2024
Q1 		$5.76K Sell
993
-920
-48% -$5.66K ﹤0.01% 2240
2023
Q4 		$12.5K Hold
1,913
– – ﹤0.01% 2107
2023
Q3 		$9.22K Hold
1,913
– – ﹤0.01% 2246
2023
Q2 		$9.76K Buy
+1,913
New +$10.3K ﹤0.01% 2309
2021
Q4 		– Sell
-3,598
Closed -$33.6K – 2833
2021
Q3 		$33.6K Sell
3,598
-5,283
-59% -$53.3K ﹤0.01% 2798
2021
Q2 		$114K Buy
+8,881
New +$95.4K ﹤0.01% 2531

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ZVRA Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Zevra Therapeutics (ZVRA) in Q2 2024, closing a stake of 993 shares — an estimated $5.76K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ZVRA in Q2 2021 and held it in 6 quarters. The position peaked at $114K in Q2 2021. 93 funds tracked by Wall St. Rank hold ZVRA as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Zevra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 993 Zevra Therapeutics shares in Q2 2024, an estimated $5.76K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Zevra Therapeutics in Q2 2021 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Zevra Therapeutics position peaked at $114K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.